Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20766725 | 0.91 | AKR1C1 (0.35) | AKR1C1HDAC4 | |
| SCHEMBL25303177 | 0.77 | AKR1C1 (0.52) | AKR1C1HDAC4 | |
| SCHEMBL28110924 | 0.74 | AKR1C1 (0.31) | AKR1C1 | |
| SCHEMBL9873993 | 0.71 | TSHR (0.42) | TSHR | |
| SCHEMBL21612179 | 0.70 | AKR1C1 (0.48) | AKR1C1HDAC4MEN1KMT2ATSHR | |
| SCHEMBL28295066 | 0.70 | HDAC4 (0.47) | AKR1C1HDAC4MEN1KMT2A | |
| SCHEMBL16111708 | 0.69 | HDAC4 (0.69) | AKR1C1HDAC4MEN1KMT2A | |
| SCHEMBL988946 | 0.68 | AKR1C1 (0.62) | AKR1C1MEN1KMT2ATSHR | |
| SCHEMBL2535205 | 0.67 | AKR1C1 (0.59) | AKR1C1TSHR | |
| SCHEMBL5637311 | 0.67 | HDAC4 (0.62) | AKR1C1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368155-A1 | ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE TLR7/8 AGONIST COMPOUNDS AND USES THEREOF | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2024-11-07 | — | — | US | disclosed |
| US-11981670-B2 | Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4257198-A2 | ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE DERIVATIVES AS TLR7/8 AGONISTS AND USES THEREOF | Dynavax Technologies Corporation (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3672969-B1 | ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE DERIVATIVES AS TLR7/8 AGONISTS AND USES THEREOF | DYNAVAX TECH CORP (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20220033400-A1 | ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE TLR7/8 AGONIST COMPOUNDS AND USES THEREOF | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2022-02-03 | — | — | US | disclosed |
| US-11124510-B2 | Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2021-09-21 | — | — | US | disclosed |
| EP-3710059-A1 | CLEAVABLE CONJUGATES OF TLR7/8 AGONIST COMPOUNDS, METHODS FOR PREPARATION, AND USES THEREOF | Dynavax Technologies Corporation (US) | 2020-09-23 | — | — | EP | disclosed |
| US-10722591-B2 | Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2020-07-28 | — | — | US | disclosed |
| EP-3672969-A1 | ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE TLR7/8 AGONIST COMPOUNDS AND USES THEREOF | Dynavax Technologies Corporation (US) | 2020-07-01 | — | — | EP | disclosed |
| US-20200199124-A1 | ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE TLR7/8 AGONIST COMPOUNDS AND USES THEREOF | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2020-06-25 | — | — | US | disclosed |
| US-10618896-B2 | Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190151462-A1 | CLEAVABLE CONJUGATES OF TLR7/8 AGONIST COMPOUNDS, METHODS FOR PREPARATION, AND USES THEREOF | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2019-05-23 | — | — | US | disclosed |
| WO-2019040491-A1 | ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE TLR7/8 AGONIST COMPOUNDS AND USES THEREOF | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10722591-B2 | Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof | TLR7, TLR8, TLR9 | AKR1C1 4648/4885HDAC4 1284/4885MEN1 2716/4885 |
| US-11981670-B2 | Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof | TLR7, TLR8, TLR3 | AKR1C1 4394/4885HDAC4 435/4885MEN1 4665/4885 |
| US-20190151462-A1 | CLEAVABLE CONJUGATES OF TLR7/8 AGONIST COMPOUNDS, METHODS FOR PREPARATION, AND USES THEREOF | TLR7, TLR8, TLR9 | AKR1C1 4648/4885HDAC4 1284/4885MEN1 2716/4885 |
| US-20240368155-A1 | ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE TLR7/8 AGONIST COMPOUNDS AND USES THEREOF | TLR7, TLR8, TLR3 | AKR1C1 4394/4885HDAC4 435/4885MEN1 4665/4885 |
| US-20200199124-A1 | ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE TLR7/8 AGONIST COMPOUNDS AND USES THEREOF | TLR7, TLR8, TLR3 | AKR1C1 4394/4885HDAC4 435/4885MEN1 4665/4885 |
| US-11124510-B2 | Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof | TLR7, TLR8, TLR3 | AKR1C1 4394/4885HDAC4 435/4885MEN1 4665/4885 |
| US-20220033400-A1 | ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE TLR7/8 AGONIST COMPOUNDS AND USES THEREOF | TLR7, TLR8, TLR3 | AKR1C1 4394/4885HDAC4 435/4885MEN1 4665/4885 |
| US-10618896-B2 | Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof | TLR7, TLR8, TLR3 | AKR1C1 4394/4885HDAC4 435/4885MEN1 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.